

**Section I. (Amendment of the Specification)**

Page 13; replace the paragraph beginning at line 1, including the chemical formula thereof, with the following replacement paragraph:

One presently preferred movement disorder-combating therapeutic composition in the general practice of the present invention comprises mirtazapine, a piperazinoazepine characterized as (i) a presynaptic alpha-2 antagonist that acts to increase noradrenergic and serotonergic neurotransmission, and (ii) a postsynaptic serotonergic 5-HT<sub>2</sub> and 5-HT<sub>3</sub> antagonist. Mirtazapine, or 6-azamianserin, includes the compound, 1,2,3,4,10,14b-hexahydro-2-methyl-pyrazino [2,1-a]pyrido [2,3-c]benzazepine) in racemic forms. The S(+) enantiomer has the formula:



